


Supplementary Material

A Phase I/II Study Targeting Angiogenesis Using Bevacizumab Combined with Chemotherapy and a Histone Deacetylase Inhibitor (Valproic Acid) in Advanced Sarcomas

Varun Monga, Umang Swami, Munir Tanas, Aaron Bossler, Sarah L. Mott, Brian J. Smith and Mohammed Milhem



Legend

- Valproic acid (VPA) dose 40mg/kg given for 5 days prior to each cycle (*days -4,-3,-2,-1 and 1)
- Bevacizumab 15mg/kg Q 4 weeks
- Gemcitabine 900mg/m² on D1 and D8 to be given over 90min
- Taxotere 75mg/m² over 1 hour on D8 after the Gemcitabine.
- Total of 6 cycles were given and disease assessed every 2 cycles with imaging
- After 6 cycles bevacizumab and VPA were continued as maintenance until disease progression




Figure S1. Schematic representation of the treatment plan and different doses of drugs used. During maintenance phase patients received Bevacizumab at 15mg/kg Q 4 weeks and Valproic acid at 40mg/kg q 4 weeks for 5 days until tumor progression.